On 25th April 2018: Gerry Davies and Justin Green will be supported by PreDiCT-TB project manager Philip Whitehead as they head to Brussels this Thursday to present a wide-ranging summary of the 5-year …
Because it’s World TB Day I’d like to share my story on how I started with TB research and what it has brought so far. Especially on this day I realise the implications …
Gerry Davies talks TB and the work of the PreDiCT-TB Consortium on World TB Day.
The American Society for Pharmacology and Therapeutics (ASCPT) is enacting its 5-year strategic plan through member-lead scientific networks. The Quantitative Pharmacology Network, chaired by Anne Heatherington from Pfizer, has led the “Influence and …
On the 7th and 8th of March the PanACEA held its inaugural meeting in Cape Town, South Africa, attended by a number of the PreDiCT-TB team including Gerry, Wilber, Derek and Stephen. The meeting …
PreDiCT-TB discussed in the latest IMI Newsletter.
The 4th PreDiCT-TB General Assembly meeting took place at Uppsala Universitet, Uppsala, Sweden on 11th/12th May 2016 and was attended by 66 people from eight countries
The 4th PreDiCT-TB General Assembly meeting will take place at Uppsala, Universitet, Uppsala, Sweden on 11th/12th May 2016 .
CPATH have now made the phase III studies including REMoxTB available to the TB community. Further information can be found here: https://c-path.org/programs/tb-pacts http://www.tballiance.org/news/new-tb-clinical-trial-data-sharing-platform-available-researchers http://medicine.st-andrews.ac.uk/blog/accelerating-tb-research
Gerry Davies reflects on the work of the PreDiCT-TB Consortium to date and plans for the next two years of the project.
Dr Justin Green, PreDiCT-TB co-coordinator, is a clinical trials physician at GSK, based in London. Having spent 15 years in the UK NHS, including being awarded a PhD in TB Immunology from Imperial College London, he received his infectious diseases specialist training certification in 2009. He now works in the Diseases of the Developing World group in a number of teams focusing mainly on TB and malaria collaborating with external bodies such as academic institutions and NGOs.
PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.
